Lofton E. Kevin's Insider Trades & SAST Disclosures
Lofton E. Kevin's most recent trade in Medtronic Plc was a trade of 2,083 Ordinary Shares done at an average price of $84.0 . Disclosure was reported to the exchange on April 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lofton E. Kevin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic Plc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 84.04 per share. | 28 Apr 2025 | 2,083 | 8,387 (0%) | 0% | 84.0 | 175,055 | Ordinary Shares |
| Medtronic Plc | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.60 per share. | 28 Apr 2025 | 216 | 8,171 (0%) | 0% | 84.6 | 18,274 | Ordinary Shares |
| Medtronic Plc | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 6,230 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Medtronic Plc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 6,422 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Gilead Sciences, Inc. | Lofton E. Kevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 29 | 3,224 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 31 | 3,194 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 30 | 3,163 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 92,653 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 May 2023 | 12,868 | 90,766 (0%) | 0% | 0 | Common Stock | |
| Medtronic Plc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 4,360 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Medtronic Plc | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 4,191 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 28 | 3,132 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 8,442 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.38 per share. | 09 Mar 2023 | 8,442 | 8,442 (0%) | 0% | 52.4 | 442,192 | Common Stock |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2022 | 26 | 3,103 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2022 | 35 | 3,077 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 35 | 3,042 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 95,192 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 92,748 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 9,830 | - | - | Restricted Stock Unit | |
| Medtronic Plc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 2,535 (0%) | 0% | 0 | Ordinary Shares | |
| Medtronic Plc | Kevin E. Lofton | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 161 | 2,374 (0%) | 0% | 103.1 | 16,601 | Ordinary Shares |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.62 per share. | 28 Apr 2022 | 16,322 | 90,525 (0%) | 0% | 25.6 | 418,251 | Common Stock |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 16,322 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 36 | 3,007 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2021 | 29 | 2,942 | - | - | Phantom Stock | |
| Rite Aid Corp. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2021 | 10,617 | 45,943 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 30 | 2,913 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 14,665 | 14,665 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 2,223 | 12,053 | - | - | Restricted Stock Unit | |
| Medtronic Plc | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 820 | 820 (0%) | 0% | 0 | Ordinary Shares | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 30 | 2,882 | - | - | Phantom Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 20,282 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.65 per share. | 22 Jan 2021 | 20,282 | 74,203 (0%) | 0% | 20.6 | 418,722 | Common Stock |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Nov 2020 | 21,720 | 53,921 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2020 | 30 | 2,818 | - | - | Phantom Stock | |
| Rite Aid Corp. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2020 | 6,682 | 35,326 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Kevin E. Lofton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2020 | 25 | 2,787 | - | - | Phantom Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges